Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Malignant Pleural Mesothelioma

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   41225   clinical trials with a EudraCT protocol, of which   6755   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    80 result(s) found for: Malignant Pleural Mesothelioma. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2004-002537-39 Sponsor Protocol Number: H3E-IT-S079 Start Date*: 2005-04-04
    Sponsor Name:ELI LILLY
    Full Title: Phase II Trial of Neoadjuvant ALIMTA plus Cisplatin followed by Surgery and Radiation in the Treatment of Pleural Mesothelioma
    Medical condition: Plaural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000599-40 Sponsor Protocol Number: Start Date*: 2012-06-13
    Sponsor Name:North Bristol NHS Trust
    Full Title: The efficacy of Indwelling Pleural Catheter placement versus IPC placement PLUS sclerosant (talc) in patients with malignant pleural effusions managed exclusively as out-patients
    Medical condition: Malignant pleural effusions
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035605 Pleural mesothelioma malignant advanced PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10066721 Pleural effusion recurrent LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035606 Pleural mesothelioma malignant localised LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035607 Pleural mesothelioma malignant recurrent PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10035598 Pleural effusion PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035608 Pleural metastases LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061352 Pleural neoplasm PT
    14.1 10042613 - Surgical and medical procedures 10035612 Pleural therapeutic procedures HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035603 Pleural mesothelioma PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10046099 Unspecified pleural effusion LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026673 Malignant pleural effusion PT
    14.1 10042613 - Surgical and medical procedures 10062754 Pleural cavity drainage LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10014313 Effusion pleural LLT
    14.1 10042613 - Surgical and medical procedures 10068942 Implantable pleural catheter insertion PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014293-17 Sponsor Protocol Number: AGO/2009/006 Start Date*: 2009-09-10
    Sponsor Name:University Hospital Ghent
    Full Title: Phase II study of cetuximab combined with cisplatin or carboplatin/pemetrexed as first line treatment in patients with malignant pleural mesothelioma.
    Medical condition: Patients with malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10059518 Pleural mesothelioma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004433-26 Sponsor Protocol Number: 3638 Start Date*: 2016-05-04
    Sponsor Name:North Bristol NHS Trust
    Full Title: Zoledronic acid in the management of malignant pleural mesothelioma - a feasibility study
    Medical condition: Malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027406 Mesothelioma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035603 Pleural mesothelioma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002876-10 Sponsor Protocol Number: ONC-2014-002 Start Date*: 2014-10-31
    Sponsor Name:Istituto Clinico Humanitas
    Full Title: A PHASE II STUDY OF THE COMBINATION OF GEMCITABINE AND IMATINIB MESYLATE IN PEMETREXED-PRETREATED PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA
    Medical condition: Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001016-11 Sponsor Protocol Number: SAKK17/16 Start Date*: 2018-01-31
    Sponsor Name:SAKK
    Full Title: Lurbinectedin Monotherapy in Patients with Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial
    Medical condition: Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005894-77 Sponsor Protocol Number: 107/2007/O/Sper Start Date*: 2007-12-18
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Phase I/II study with cisplatin and pemetrexed +/- sorafenib in malignant pleural mesothelioma (SoMe study)
    Medical condition: malignant pleural mesothelioma (MPM)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059518 Pleural mesothelioma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004573-95 Sponsor Protocol Number: ALIMESO-0604 Start Date*: 2007-03-22
    Sponsor Name:Centre Oscar Lambret
    Full Title: Etude pharmacologique du Pemetrexed (Alimta) administré avec Cisplatine et supplémentation vitaminique chez des patients porteurs d'un mésothéliome pleural non résécable
    Medical condition: mésothéliome pleural
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035605 Pleural mesothelioma malignant advanced LLT
    9.1 10035606 Pleural mesothelioma malignant localised LLT
    9.1 10059518 Pleural mesothelioma malignant LLT
    9.1 10035607 Pleural mesothelioma malignant recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000445-19 Sponsor Protocol Number: SAKK 17/04 Start Date*: 2007-07-27
    Sponsor Name:Swiss group for clinical cancer research
    Full Title: Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy. A randomized multicenter phase II trial
    Medical condition: Patients with pleural mesothelioma, T<=3, N<=2, M0 (IMIG-system)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035603 Pleural mesothelioma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005171-95 Sponsor Protocol Number: MESOT-TREM-2008 Start Date*: 2008-09-15
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMANIZED ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA
    Medical condition: PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059518 Pleural mesothelioma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004429-27 Sponsor Protocol Number: ONC-2006-003 Start Date*: 2007-05-25
    Sponsor Name:ISTITUTO CLINICO HUMANITAS
    Full Title: Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma
    Medical condition: Histologically proven diagnosis of malignant pleural mesothelioma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059518 Pleural mesothelioma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000949-11 Sponsor Protocol Number: 0683-014 Start Date*: 2005-07-06
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (L-001079038) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated Wit...
    Medical condition: Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    7.1 10027406 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) GR (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005201-48 Sponsor Protocol Number: 1199.93 Start Date*: 2013-07-16
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: LUME-Meso: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combina...
    Medical condition: Unresectable Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended) GB (Completed) FR (Completed) DK (Temporarily Halted) ES (Prematurely Ended) BE (Completed) NL (Prematurely Ended) SE (Completed) PT (Completed) CZ (Completed) AT (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2010-024496-37 Sponsor Protocol Number: 1716-12 Start Date*: 2012-05-04
    Sponsor Name:Virttu Biologics Limited
    Full Title: A PHASE I/IIa STUDY OF THE SAFETY, TOLERABILITY AND BIOLOGICAL EFFECT OF SINGLE AND REPEAT ADMINISTRATION OF THE SELECTIVELY REPLICATION-COMPETENT HERPES SIMPLEX VIRUS HSV1716 INTO THE TUMOUR-BEAR...
    Medical condition: Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004727-23 Sponsor Protocol Number: 3850 Start Date*: 2017-06-19
    Sponsor Name:North Bristol NHS Trust Research & Innovation
    Full Title: A Trial of Intra-pleuraL OK-432 Therapy in mesothelioma (TILT): A feasibility study using the ‘trial within a cohort’ methodology
    Medical condition: Malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-002721-30 Sponsor Protocol Number: NIPU Start Date*: 2021-01-14
    Sponsor Name:Oslo University Hospital
    Full Title: Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study)
    Medical condition: Malignant pleural mesothelioma (MPM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003169-82 Sponsor Protocol Number: rAd-IFN-MM-301 Start Date*: 2019-01-30
    Sponsor Name:Trizell Ltd
    Full Title: A Phase III, Open Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination wit...
    Medical condition: Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) FR (Ongoing) PL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003830-34 Sponsor Protocol Number: 415-13 Start Date*: 2014-05-15
    Sponsor Name:Asklepios Fachkliniken München Gauting
    Full Title: Pleurectomy/decortication and hypterthermic intrathoracic chemotherapy compared to pleurectomy/decortication in patients with malignant pleural mesothelioma
    Medical condition: malignant pleuramesothelioma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027407 Mesothelioma malignant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004475-75 Sponsor Protocol Number: IFCT-1501 Start Date*: 2016-02-08
    Sponsor Name:IFCT
    Full Title: A randomized phase II study evaluating efficacy and safety of 2nd or 3rd line treatment by Nivolumab monotherapy or Nivolumab plus Ipilimumab, for unresectable Malignant Pleural Mesothelioma (MPM) ...
    Medical condition: Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001992-30 Sponsor Protocol Number: Start Date*: 2015-04-20
    Sponsor Name:University of Leicester
    Full Title: A randomised controlled phase II trial of oral vinorelbine as second line therapy for patients with malignant pleural mesothelioma
    Medical condition: Histologically confirmed malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA